Analysts estimate that Collegium Pharmaceutical will report an earnings per share (EPS) of $1.59.
Anticipation surrounds Collegium Pharmaceutical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Earnings History Snapshot
Last quarter the company beat EPS by $0.11, which was followed by a 0.51% increase in the share price the next day.
Here's a look at Collegium Pharmaceutical's past performance and the resulting price change:
Quarter
Q2 2024
Q1 2024
Q4 2023
Q3 2023
EPS Estimate
1.51
0.75
0.66
0.52
EPS Actual
1.62
1.45
1.58
1.34
Price Change %
1.0%
-17.0%
11.0%
7.000000000000001%
Collegium Pharmaceutical Share Price Analysis
Shares of Collegium Pharmaceutical were trading at $33.42 as of November 05. Over the last 52-week period, shares are up 42.5%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Views on Collegium Pharmaceutical
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Collegium Pharmaceutical.
The consensus rating for Collegium Pharmaceutical is Buy, derived from 4 analyst ratings. An average one-year price target of $41.5 implies a potential 24.18% upside.
Comparing Ratings with Competitors
The ...
